TBCA

Tubulin-specific chaperone A · O75347 · TBCA on Sugi Atlas →

0 patent compounds predicted against TBCA, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to TBCA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome) PHASE2/PHASE3UNKNOWN
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer PHASE3COMPLETED
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
High-Dose Ambroxol in GBA1-Related Parkinson PHASE1/PHASE2UNKNOWN
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis PHASE2COMPLETED
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease PHASE2COMPLETED
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia PHASE1/PHASE2NOT_YET_RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies PHASE1WITHDRAWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas PHASE1COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma PHASE1COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery PHASE1COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors PHASE1COMPLETED
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis PHASE1WITHDRAWN
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Perfusion-Induced Hyperthermia for Metastatic Carcinoma nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC nanCOMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases. nanNOT_YET_RECRUITING
Effect of Low Dose of Colchicine on Platelet Reactivity nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TBCA binder may also engage these)

ProteinNameSimilarity
Q6PEC1 1.000 Q6PEC1 →
P48427 1.000 P48427 →
P80584 1.000 P80584 →
P48428 0.997 P48428 →
P80585 0.982 P80585 →
O04350 0.979 O04350 →
Q6N069 0.950 Q6N069 →
Q5XGY9 0.949 Q5XGY9 →
Q5ZLF0 0.948 Q5ZLF0 →
P50503 0.946 P50503 →
ENY2 Transcription and mRNA export factor ENY2 0.945 landscape →
Q3ZBJ0 0.945 Q3ZBJ0 →
Q9SWE7 0.943 Q9SWE7 →
Q80UM3 0.943 Q80UM3 →
Q5RE03 0.943 Q5RE03 →
Q9JIX0 0.943 Q9JIX0 →
B5FZ63 0.942 B5FZ63 →
A4QNE0 0.941 A4QNE0 →
Q6P643 0.941 Q6P643 →
Q5R4J9 0.941 Q5R4J9 →
NAA15 N-alpha-acetyltransferase 15, NatA auxiliary subunit 0.941 landscape →
USO1 General vesicular transport factor p115 0.940 landscape →
Q2HJ41 0.940 Q2HJ41 →
PIK3R1 Phosphatidylinositol 3-kinase regulatory subunit alpha 0.940 landscape →
Q8RWF0 0.940 Q8RWF0 →
Q8K396 0.939 Q8K396 →
P50502 0.939 P50502 →
Q8NFI4 0.939 Q8NFI4 →
Q8IZP2 0.939 Q8IZP2 →
P37285 0.939 P37285 →